How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Download this article in PDF format. Switching losses are inevitable in any power device. But these losses can be minimized through optimization and rigorous measurement of design parameters related ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Psychology Today's online self-tests are intended for informational purposes only and are not diagnostic tools. Psychology Today does not capture or store personally identifiable information, and your ...

Carley Millhone is a writer and editor based in the Midwest who covers health, women's wellness, and travel. Her work has appeared in publications like SELF, Greatist, and PureWow. Jay N. Yepuri, MD, ...